Preparation method of beta-blocker for injection
Through the improved lyophilization process, including prefreezing, one drying and two analytical drying processes, the problem of insufficient stability and shelf life of lycodilian hydrochloride for injection is solved, and the rapid redissolution and efficient treatment of the drug are achieved.
Patent Information
- Application Number
- CN202411175929.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The stability and shelf life of the existing lycyrrhiolol hydrochloride for injection are insufficient, and the redissolution rate is slow in the case of emergency medication, which affects the treatment efficiency.
The improved lyophilization process is adopted, including prefreezing, one drying and two analytical drying processes. By precisely controlling the temperature and time, the changes in the molecular structure of the drug are reduced, and the loose porous structure is formed, and the stability and solubility of the drug are improved.
It significantly improves the stability and shelf life of lycidolol hydrochloride injection, ensures rapid redissolution of the drug, and improves the treatment efficiency and timeliness of emergency medication.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of pharmaceutical preparations, and in particular relates to a method for preparing a beta-blocker for injection. Background Art
[0002] Landiolol hydrochloride for injection is an injectable drug preparation developed by Ono Pharmaceutical of Japan for the treatment of tachyarrhythmias. It is a new type of ultra-short-acting adrenergic beta-receptor blocker. Ultra-short-acting adrenergic beta-receptor blockers play an important and irreplaceable role in the treatment of newly occurring tachyarrhythmias due to their rapid onset of action, rapid metabolism, and rapid disappearance of beta-receptor blocking effects after drug withdrawal. It is clinically applicable to 1. Emergency treatment of the following tachyarrhythmias occurring during surgery: atrial fibrillation, atrial flutter, and sinus tachycardia; 2. Emergency treatment of tachyarrhythmias occurring during dynamic monitoring of the circulatory system after surgery: atrial fibrillation, atrial flutter, and sinus tachycardia; 3. Treatment of the following tachyarrhythmias in patients with heart failure: atrial fibrillation and atrial flutter.
[0003] Patent CN101732319B discloses a pharmaceutical composition for injection containing the active ingredient of landiolol hydrochloride and a preparation method thereof, wherein a freeze-dried preparation of landiolol hydrochloride for injection is obtained by freeze drying.
[0004] Patent CN102475706A discloses a landiolol hydrochloride pharmaceutical composition for injection and a preparation method thereof. The method involves mixing landiolol, sodium calcium edetate and lactose, and preparing a lyophilized formulation of landiolol hydrochloride for injection by freeze-drying technology.
[0005] CN102232930A discloses a landiolol hydrochloride pharmaceutical composition and a preparation method thereof. Amino acids are used as excipients and the temperature of injection water and the pH value of the solution are controlled to obtain a landiolol hydrochloride lyophilized preparation.
[0006] The contents described in the above patents are all intended to solve the stability problem of landiolol hydrochloride for injection, but the effects that can be achieved are limited. Summary of the invention
[0007] In order to solve the problems existing in the prior art, the present invention provides a method for preparing a beta-blocker for injection, comprising the following steps:
[0008] 1) preparing a liquid: mixing a prescribed amount of landiolol hydrochloride, a prescribed amount of a lyophilization protective agent and a portion of a solvent, stirring and dissolving, adjusting the pH value of the liquid with a sodium hydroxide solution, and diluting the volume to a predetermined volume with the solvent to obtain a landiolol hydrochloride liquid;
[0009] 2) Filtration: filtering the landiolol hydrochloride solution obtained in step 1) using a filter membrane;
[0010] 3) Filling: filling the landiolol hydrochloride solution filtered in step 2) into an injection bottle to obtain a landiolol hydrochloride product 1;
[0011] 4) semi-plugging: performing semi-plugging treatment on the landiolol hydrochloride product 1 to obtain the landiolol hydrochloride product 2;
[0012] 5) freeze drying: freeze drying the landiolol hydrochloride product 2 through pre-freezing, primary drying and secondary analytical drying steps to obtain the landiolol hydrochloride product 3;
[0013] 6) nitrogen filling, plugging, and unpacking: nitrogen filling the landiolol hydrochloride product 3 under vacuum, and then plugging in a freeze dryer before unpacking;
[0014] 7) Capping: The product obtained in step 6) is capped to obtain the final landiolol hydrochloride product 4.
[0015] Furthermore, the pre-freezing process in step 5) is: placing the landiolol hydrochloride product 2 into a freeze-drying chamber, setting the temperature of the heat transfer liquid to -30°C, and lowering the temperature of the landiolol hydrochloride product 2 to -30°C±5°C within 60 minutes, and then maintaining it within this temperature range for 60 to 120 minutes.
[0016] Furthermore, the primary drying process in step 5) is as follows: after the pre-freezing process is completed, when the vacuum degree in the freeze drying chamber reaches 0.15 mbar, the temperature is started to rise, so that the temperature of the heat transfer liquid is slowly raised to 10-15°C, and the heating time is controlled within 60 minutes, and then kept warm at this temperature for 180-720 minutes.
[0017] Furthermore, the two analytical drying processes in step 5) are as follows: first analytical drying: after the first drying process is completed, the heat transfer system is started to raise the temperature of the thermal fluid to 30-40°C, and the heating time is controlled within 60 minutes, and then kept warm at this temperature for 60-120 minutes, while maintaining the vacuum degree in the freeze drying chamber at 0.1 mbar; second analytical drying: after the first analytical drying is completed, the vacuum degree in the freeze drying chamber is gradually adjusted to 0 mbar, and while adjusting the vacuum degree, the temperature of the thermal fluid is maintained at 30-40°C for 60-120 minutes.
[0018] Further, the temperature of the heat transfer liquid in the first desorption drying is the same as the temperature of the heat transfer liquid in the second desorption drying.
[0019] Furthermore, the pH value of the landiolol hydrochloride solution is 5.5-6.5.
[0020] Furthermore, the composition of the beta-blocker for injection includes: 50-55 parts of landiolol hydrochloride, 50-55 parts of lyophilization protectant, an appropriate amount of sodium hydroxide and an appropriate amount of solvent.
[0021] Furthermore, the lyophilization protective agent is D-mannitol.
[0022] Furthermore, the solvent is used to adjust the volume of the mixture of landiolol hydrochloride and the lyoprotectant to a predetermined volume of each preparation.
[0023] On the other hand, the present invention provides a beta-blocker for injection prepared according to the above method, wherein the beta-blocker for injection is preferably landiolol hydrochloride for injection, and the dosage form is sterile powder for injection.
[0024] Compared with the prior art, the preparation method of the beta-blocker for injection (hereinafter referred to as "landiolol hydrochloride for injection") of the present invention has the following advantages:
[0025] (1) By improving the freeze-drying process, the preparation method of the present invention can significantly improve the stability of landiolol hydrochloride injection. During the freeze-drying process, by accurately controlling parameters such as temperature and time, the structural changes of drug molecules during the freeze-drying process are reduced, thereby maintaining its efficacy.
[0026] (2) The optimized freeze-drying process allows the prepared injection to have a longer shelf life. This is due to the removal of water and the stabilization of the drug during the freeze-drying process, which reduces the degradation rate of the drug during storage.
[0027] (3) The improved freeze-drying process significantly improves the solubility of landiolol hydrochloride in water or other solvents. The drug after freeze-drying presents a loose and porous structure, which greatly increases the contact area between the drug and the solvent, thereby greatly promoting the rapid and complete dissolution of the drug. Thanks to this, the landiolol hydrochloride injection obtained by the preparation method of the present invention can be quickly re-dissolved, which is particularly important in emergency medication situations, ensuring the high efficiency and timeliness of treatment. DETAILED DESCRIPTION
[0028] The technical solutions in the embodiments of the present application will be described clearly below. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments in the present application belong to the scope of protection of the present application.
[0029] The terms "first", "second", etc. in the specification and claims of this application are used to distinguish similar objects, and are not used to describe a specific order or sequence. It should be understood that the data used in this way can be interchangeable under appropriate circumstances, so that the embodiments of the present application can be implemented in an order other than those described here, and the objects distinguished by "first", "second", etc. are generally of one type, and the number of objects is not limited. For example, the first object can be one or more. In addition, "and / or" in the specification and claims represents at least one of the connected objects, and the character " / " generally indicates that the objects associated before and after are in an "or" relationship.
[0030] The inventors of the present application have found that by controlling the key steps in the method for preparing landiolol hydrochloride for injection, the stability of landiolol hydrochloride injection can be significantly improved and the shelf life of the drug can be extended. The entire process includes the following main steps:
[0031] 1) preparing a liquid: mixing a prescribed amount of landiolol hydrochloride, a prescribed amount of a lyophilization protective agent and a portion of a solvent, stirring and dissolving, adjusting the pH value of the liquid with a sodium hydroxide solution, and diluting the volume to a predetermined volume with the solvent to obtain a landiolol hydrochloride liquid;
[0032] In one embodiment of the present invention, the amount of landiolol hydrochloride is 50-55 parts, and the amount of lyoprotectant is 50-55 parts; in one embodiment of the present invention, the lyoprotectant is D-mannitol; in one embodiment of the present invention, the pH value of the landiolol hydrochloride solution is 5.5-6.5, for example, 5.5, 5.9, 6.0, 6.1 or 6.5, but is not limited to the listed values, and other values not listed within the numerical range are also applicable;
[0033] 2) Filtration: filtering the landiolol hydrochloride solution obtained in step 1) using a filter membrane;
[0034] 3) Filling: filling the landiolol hydrochloride solution filtered in step 2) into an injection bottle to obtain a landiolol hydrochloride product 1;
[0035] 4) Semi-plugging: The landiolol hydrochloride product 1 is semi-plugged to obtain the landiolol hydrochloride product 2; the semi-plugging is mainly used to ensure the stability of the freeze-dried product during the drying process and the quality of the final product. The operation is to gently push the plug into the bottle mouth, but not completely seal it.
[0036] 5) freeze drying: freeze drying the landiolol hydrochloride product 2 through pre-freezing, primary drying and secondary analytical drying steps to obtain the landiolol hydrochloride product 3;
[0037] Specifically, the process includes the following steps:
[0038] A. Pre-freezing: Place the landiolol hydrochloride product 2 in a freeze-drying chamber, set the temperature of the heat transfer fluid to -30°C, and reduce the temperature of the landiolol hydrochloride product 2 to -30°C±5°C within 60 minutes, and then maintain it within the temperature range for 60 to 120 minutes, such as 60 minutes, 90 minutes or 120 minutes, but not limited to the listed values, and other values not listed within the numerical range are also applicable;
[0039] B. Primary drying: When the vacuum degree in the freeze drying chamber reaches 0.15 mbar, the temperature is raised to slowly raise the temperature of the thermal conduction fluid to 10-15°C, such as 10°C, 11°C, 12°C, 13°C, 14°C or 15°C, but not limited to the listed values, and other values not listed in the numerical range are also applicable; the heating time is controlled within 60 minutes, and then the temperature is kept at this temperature for 180-720 minutes, such as 180 minutes, 240 minutes, 300 minutes, 360 minutes, 420 minutes, 480 minutes, 540 minutes, 600 minutes, 660 minutes or 720 minutes, but not limited to the listed values, and other values not listed in the numerical range are also applicable;
[0040] C. First analytical drying: After step B is completed, the heat transfer system is started to raise the temperature of the heat transfer liquid to 30-40°C, for example, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C or 40°C, but not limited to the listed values, other values not listed in the numerical range are also applicable; the heating time is controlled within 60 minutes, and then the temperature is kept at this temperature for 60-120 minutes, for example, 60 minutes, 90 minutes or 120 minutes, but not limited to the listed values, other values not listed in the numerical range are also applicable, and at the same time, the vacuum degree in the freeze drying chamber is maintained at 0.1 mbar;
[0041] D. Second analytical drying: After step C is completed, gradually adjust the vacuum degree in the freeze drying chamber to 0 mbar. While adjusting the vacuum degree, maintain the temperature of the thermal transfer liquid at 30-40°C, for example, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C or 40°C, but are not limited to the listed values, and other values not listed within the numerical range are also applicable; keep warm for 60-120 minutes.
[0042] The control of temperature and time during the freeze-drying process is crucial to maintaining the active ingredients of the drug. By precisely controlling the temperature and time during the freeze-drying process, the structural changes of the drug molecules can be reduced, thereby maintaining its efficacy and ensuring the stability of landiolol hydrochloride for injection. At the same time, the control of temperature and time during the freeze-drying process will also affect the solubility of the drug. Appropriate temperature and time help to form a loose and porous freeze-dried structure, thereby improving the solubility of landiolol hydrochloride for injection in water or other solvents.
[0043] 6) Nitrogen filling, plugging, and unpacking: The landiolol hydrochloride product 3 is filled with nitrogen under vacuum, and then plugged in a freeze dryer before unpacking; plugging refers to completely sealing the plug at the bottle mouth.
[0044] 7) Capping: The product obtained in step 6) is capped to obtain the final landiolol hydrochloride product 4.
[0045] The following are specific examples of the present invention and comparative examples, but the present invention is not limited to the following examples.
[0046] The sources of raw materials and supplementary materials for the embodiments and comparative examples are as follows:
[0047] Product Name batch number Manufacturer Landiolol Hydrochloride 231110 Beijing Sun Novo Pharmaceutical Research Co., Ltd. D-Mannitol F835E Guangxi Nanning Chemical Pharmaceutical Co., Ltd. Sodium hydroxide 100920211214 Hunan Erkang Pharmaceutical Co., Ltd. Watsons Water 20220609R Guangzhou Watsons Food and Beverage Co., Ltd.
[0048] The production equipment of the embodiments and comparative examples are as follows:
[0049] Device Name Device Model Equipment manufacturers Freeze Dryer LYO-0.5 Tungfulong Technology Co., Ltd. Pneumatic capping machine SUS304-8 Foshan Lianxing Yongsheng Steel Pipe Co., Ltd.
[0050] Example 1
[0051] Prescription composition:
[0052] Name of raw materials Unit dose 600 pieces effect Landiolol Hydrochloride 50mg 30.04g Active substances D-Mannitol 50mg 30g Lyoprotectant Sodium hydroxide solution Moderate / pH Adjusters Watsons Water Make up to 1ml 600ml Solvents
[0053] Preparation process:
[0054] 1) Preparation: 0.1M sodium hydroxide solution: stir 2.0g sodium hydroxide and add 500ml water for injection, stir well and set aside. Measure 70% of the prescribed amount of Watson's water and add it to a beaker. Add the prescribed amount of D-mannitol while stirring, start stirring to dissolve the mannitol, then add the prescribed amount of landiolol hydrochloride to dissolve, adjust the pH value to 5.5-6.5 with sodium hydroxide solution, transfer the liquid to a measuring cylinder, rinse the beaker several times with Watson's water, dilute to 600ml, and then start stirring again for 10 minutes.
[0055] 2) Filtration: Filter the landiolol hydrochloride solution obtained in step 1) using a PES filter membrane with a pore size of 0.22 μm and set aside.
[0056] 3) Filling: Fill the landiolol hydrochloride solution filtered in step 2) into an injection bottle to obtain the landiolol hydrochloride product 1.
[0057] 4) Semi-plugging: The landiolol hydrochloride product 1 is subjected to a semi-plugging treatment to obtain the landiolol hydrochloride product 2.
[0058] 5) Freeze-drying: The landiolol hydrochloride product 2 was freeze-dried according to the following parameters.
[0059]
[0060] The specific operations are:
[0061] Pre-freezing: Place the landiolol hydrochloride product 2 into a freeze-drying chamber, set the temperature of the heat transfer liquid to -30°C according to the freeze-drying process, so as to reduce the temperature of the landiolol hydrochloride product 2 to -30°C ± 5°C within 60 minutes, and then maintain it within this temperature range for 60 minutes.
[0062] Primary drying (freeze drying): After the pre-freezing process is completed, when the vacuum degree in the freeze drying chamber reaches 0.15mbar, start heating and slowly raise the temperature of the thermal transfer liquid to 10°C. The heating time is controlled within 60 minutes, and then keep warm at this temperature for 720 minutes.
[0063] First analytical drying: After the first drying is completed, the heat transfer system is started to raise the temperature of the heat transfer fluid to 40°C. The heating time is controlled within 60 minutes, and then the temperature is kept at this temperature for 120 minutes. During this period, the vacuum degree in the freeze drying chamber is maintained at 0.1 mbar.
[0064] Second analytical drying: After the first analytical drying, the vacuum degree in the freeze drying chamber was gradually adjusted to 0 mbar. While adjusting the vacuum degree, the temperature of the heat transfer liquid was kept constant at 40°C for 60 minutes to obtain landiolol hydrochloride product 3.
[0065] 6) Nitrogen filling, plugging, and unpacking: Under vacuum, the freeze-dried landiolol hydrochloride product 3 is filled with nitrogen at a nitrogen filling rate of 100%, plugged in the freeze dryer, and then unpacked.
[0066] 7) Capping: The product obtained in step 6) is capped with an air-operated capping machine on the aluminum-plastic composite cap of the antibiotic bottle to obtain the final landiolol hydrochloride product 4.
[0067] Example 2
[0068] The temperature of the two analytical dryings in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0069]
[0070] Example 3
[0071] The duration of pre-freezing in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0072]
[0073] Example 4
[0074] The duration of the primary drying in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0075]
[0076] Example 5
[0077] The duration of the primary drying in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0078]
[0079] Example 6
[0080] The duration of the first analytical drying in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0081]
[0082]
[0083] Comparative Example 1
[0084] Step 5) There is only one analytical drying process, and the specific freeze-drying parameters are as shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0085]
[0086] Comparative Example 2
[0087] The temperature of the two analytical dryings in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0088]
[0089] Comparative Example 3
[0090] The duration of pre-freezing in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0091]
[0092] Comparative Example 4
[0093] The duration of the primary drying in step 5) was adjusted. The specific freeze-drying parameters are as shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0094]
[0095] Comparative Example 5
[0096] The duration of the primary drying in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0097]
[0098] Comparative Example 6
[0099] The duration of the first analytical drying in step 5) was adjusted. The specific freeze-drying parameters are as shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0100]
[0101] Comparative Example 7
[0102] The temperature of the first drying and the second analytical drying in step 5) was adjusted. The specific freeze-drying parameters are shown in the following table. The specific operation, formulation composition and other process steps and conditions are the same as those in Example 1.
[0103]
[0104]
[0105] Comparative Example 8
[0106] Step 5) The freeze-drying process refers to patent CN102232930A, and the formulation composition and other process steps and conditions are the same as those in Example 1. The specific operation of the freeze-drying process is:
[0107] Place the product in a freeze-drying box, close the door, start refrigeration, and use heat transfer oil to lower the temperature of the product. When the product temperature reaches below the eutectic point, continue freezing for 2 hours. When the product temperature reaches -45°C, stop the heat transfer oil and turn on the condenser. When the condenser temperature reaches -50°C, turn on the vacuum system and increase the temperature by 2 to 4°C per hour for sublimation drying. The final drying temperature is 45°C, and this temperature is maintained for 4 hours.
[0108] Determination of Examples 1 to 6, Comparative Examples 1 to 8 and commercially available landiolol hydrochloride for injection (the commercially available product is produced by Ono Pharmaceutical Industry Co., Ltd.) (Batch: 168YA)) Related substances of the product on day 0 and after being placed under strong light (5000 lux), high temperature (60°C) and high humidity (RH90%) conditions for 10 days.
[0109] Determination method of related substances
[0110] Determined by high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512)
[0111] Solvent water-acetonitrile (9:1)
[0112] Test solution Take the product, dissolve it in solvent and dilute it to make a solution containing about 1.0 mg of landiol hydrochloride per 1 ml. Control solution Accurately measure an appropriate amount of the test solution and dilute it with solvent to make a solution containing about 2.0 μg per 1 ml.
[0113] System suitability solution Take appropriate amount of impurities YLDZ-SM-B, YLDZ-IM-A, YLDZ-IM-B, YLDZ-IM-C, YLDZ-IM-H reference substances and landiolol hydrochloride, dissolve and dilute with solvent to make a mixed solution containing about 2.0 μg each of YLDZ-SM-B, YLDZ-IM-A, YLDZ-IM-B, YLDZ-IM-C, YLDZ-IM-H and about 1.0 mg of landiolol hydrochloride per 1 ml.
[0114] Sensitivity solution: Accurately measure an appropriate amount of the reference solution and dilute it with solvent to make a solution containing about 0.2 μg per 1 ml.
[0115] Chromatographic conditions: Octadecylsilane bonded silica gel as filler (YMC-Pack ODS-AQ, 4.6 mm × 250 mm, 5 μm or chromatographic column of equivalent performance); 0.05 mol / L sodium dihydrogen phosphate (1 mol / L sodium hydroxide adjusted to pH 4.8)-acetonitrile (90:10) as mobile phase A, 0.05 mol / L sodium dihydrogen phosphate (1 mol / L sodium hydroxide adjusted to pH 4.8)-acetonitrile (30:70) as mobile phase B; flow rate 1.0 ml per minute; column temperature 30 ° C; detection wavelength 220 nm; injection volume 20 μl. Elution was performed according to the following gradient
[0116] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 100 0 5 100 0 10 70 30 35 20 80 40 20 80 45 100 0 55 100 0
[0117] System suitability requirements In the system suitability solution chromatogram, the peak order is impurity YLDZ-IM-A, YLDZ-IM-B, YLDZ-IM-H, landiolol hydrochloride, YLDZ-SM-B, YLDZ-IM-C, and the separation between the main peak and the adjacent chromatographic peak should be no less than 1.5. The theoretical plate number calculated based on landiolol should be no less than 5000. In the system suitability solution chromatogram, the signal-to-noise ratio of the main component peak height should be no less than 10
[0118] Determination method: Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph, and record the chromatogram
[0119] If there are impurity peaks in the chromatogram of the limit test solution, after deducting the blank solvent peak, according to the self-control method, the peak area of each known impurity shall not be greater than 3 times the main peak area of the control solution (0.3%). The peak area of other individual impurities shall not be greater than 2.0 times the main peak area of the control solution (0.2%), and the sum of the peak areas of each impurity shall not be greater than 10 times the main peak area of the control solution (1.0%). Impurity peaks smaller than the peak area of Pemabet in the sensitivity solution (0.02%) can be ignored.
[0120] The impurity information of Landiolol Hydrochloride for Injection is as follows:
[0121]
[0122]
[0123] The results of the related substance detection of the embodiments and comparative examples are as follows:
[0124]
[0125]
[0126]
[0127]
[0128] From the test results of related substances in the embodiments and comparative examples, it can be seen that the impurity content of Examples 1 to 6 is similar to or even lower than the impurity content level of commercially available products.
[0129] There are two analytical drying steps in Examples 1 to 6, while Comparative Example 1 has only one analytical drying step. The content of impurity YLDZ-IM-B in landiolol hydrochloride for injection obtained in Comparative Example 1 is 0.28% on day 0, which is too high compared with the contents in the embodiments and commercially available products, and the content of total impurities in Comparative Example 1 after being placed under high temperature (60° C.) for 10 days is 0.92%, which is too high compared with Examples 1 to 6.
[0130] In Examples 1 to 6, the temperature of the first drying and second drying analysis is 30 to 40° C., in Comparative Example 2, the temperature of the first drying and second drying analysis is increased to 45° C., and in Comparative Example 7, the temperature of the first drying and second drying analysis is reduced to 25° C. The content of impurity YLDZ-IM-B in the landiolol hydrochloride for injection obtained in Comparative Example 2 is 0.3% on day 0, reaching the limit value, and after being placed under different conditions for 10 days, the content of impurity YLDZ-IM-B exceeds the limit of 0.3%; at the same time, the content of total impurities after being placed under high temperature (60° C.) for 10 days is 1.08%, which is too high compared with Examples 1 to 6, and exceeds the limit of 1.0%; the content of other single impurities after being placed under high temperature (60° C.) for 10 days is 0.37%, exceeding the limit value of 0.2%. The total impurity content of landiolol hydrochloride for injection obtained in Comparative Example 7 was 1.02% after being placed under high temperature (60°C) conditions for 10 days, which was too high compared with Examples 1 to 6 and exceeded the limit of 1.0%. At the same time, the content of impurity YLDZ-IM-B on day 0 had reached 0.3%, reaching the limit value, and after being placed under different conditions for 10 days, the content of impurity YLDZ-IM-B exceeded the limit of 0.3%.
[0131] The duration of prefreezing in Examples 1 to 6 is 60 to 120 minutes, and the duration of prefreezing in Comparative Example 3 is adjusted to 180 minutes. From the relevant material data, the total impurity content of landiolol hydrochloride for injection obtained in Comparative Example 3 is 1.06% after being placed under high temperature (60°C) for 10 days, exceeding the limit of 1.0%. At the same time, the content of impurity YLDZ-IM-B on the 0th day has reached 0.31%, reaching the limit value, and after being placed under different conditions for 10 days, the content of impurity YLDZ-IM-B exceeds the limit of 0.3%.
[0132] In Examples 1 to 6, the duration of a drying cycle is 180 to 720 minutes, in Comparative Example 4, the duration of a drying cycle is adjusted to 120 minutes, and in Comparative Example 5, the duration of a drying cycle is adjusted to 780 minutes. From the data of the relevant substances, the content of impurity YLDZ-IM-B in Comparative Example 4 has reached 0.3% on the 0th day, reaching the limit value, and after being placed under different conditions for 10 days, the content of impurity YLDZ-IM-B has exceeded the limit of 0.3%; at the same time, the content of total impurities placed under high temperature (60°C) for 10 days is 0.97%, which is too high compared with Examples 1 to 6. In Comparative Example 5, the content of impurity YLDZ-IM-B has reached 0.31% on the 0th day, reaching the limit value, and after being placed under different conditions for 10 days, the content of impurity YLDZ-IM-B has exceeded the limit of 0.3%; the content of total impurities placed under high temperature (60°C) for 10 days is 0.95%, which is too high compared with Examples 1 to 6.
[0133] The duration of the first analytical drying in Examples 1 to 6 is 60 to 120 minutes, and the duration of the first analytical drying in Comparative Example 6 is extended to 180 minutes. According to the relevant material data, the content of other single impurities in the landiolol hydrochloride for injection obtained in Comparative Example 6 after being placed under high temperature (60° C.) for 10 days is 0.33%, which exceeds the limit value of 0.2%, and the content of total impurities after being placed under high temperature (60° C.) for 10 days is 0.93%, which is too high compared with Examples 1 to 6.
[0134] At the same time, the inventor used the freeze-drying process of the existing patent CN102232930A as comparative example 8 to further investigate the effects of different freeze-drying processes on related substances. Under the same other conditions as in Example 1, the total impurity content of landiolol hydrochloride for injection obtained in comparative example 8 was 1.07% after being placed at high temperature (60°C) for 10 days, which exceeded the limit of 1.0%, and the content of other single impurities after being placed at high temperature (60°C) for 10 days was 0.32%, which exceeded the limit of 0.2%, and the content of impurity YLDZ-IM-B on day 0 had reached 0.29%. After being placed under different conditions for 10 days, the content of impurity YLDZ-IM-B had exceeded the limit of 0.3%.
[0135] It can be seen that in order to ensure that the obtained landiolol hydrochloride for injection has excellent stability, each link of the freeze-drying process - pre-freezing, primary drying, first desorption drying and second desorption drying - is indispensable. In addition, the parameters of each link must be maintained within a specific range.
[0136] Determination of Examples 1 to 6, Comparative Examples 1 to 8 and commercially available landiolol hydrochloride for injection (the commercially available product is produced by Ono Pharmaceutical Industry Co., Ltd.) (Batch: 168YA)) reconstitution time.
[0137] Determination method : Add 20-25℃ sterile water for injection according to the labeled amount and shake gently. It should be completely dissolved within 15 minutes.
[0138] The results of the re-dissolution time test of the embodiment and the comparative example are as follows:
[0139] batch Reconstitution time Commercially available products 43 seconds Example 1 38 seconds Example 2 37 seconds Example 3 44 seconds Example 4 42 seconds Example 5 41 seconds Example 6 39 seconds Comparative Example 1 1 minute 58 seconds Comparative Example 2 2 minutes 05 seconds Comparative Example 3 2 minutes 21 seconds Comparative Example 4 2 minutes 15 seconds Comparative Example 5 1 minute 45 seconds Comparative Example 6 2 minutes 22 seconds Comparative Example 7 2 minutes 19 seconds Comparative Example 8 2 minutes 31 seconds
[0140] From the re-dissolution time test results of the embodiments and the comparative examples, it can be seen that the re-dissolution time of embodiments 1 to 6 is similar to that of the commercially available products, while the re-dissolution time of the comparative examples is longer than that of the embodiments and the commercially available products. For emergency drugs such as landiolol hydrochloride for injection, the re-dissolution time is directly related to life safety and is an extremely critical influencing factor.
[0141] The freeze-drying process is widely used in the pharmaceutical field, and usually includes pre-freezing, primary drying (sublimation drying) and secondary drying (analytical drying). However, because landiolol hydrochloride for injection is an ultra-short-acting adrenergic β-receptor blocker, it has the characteristics and requirements of rapid onset and rapid metabolism, which makes it have higher requirements for the freeze-drying process.
[0142] The inventors of the present application have found that rapid freezing is required in the pre-freezing stage of the freeze-drying process to reduce the size of ice crystals and avoid cell death, thereby ensuring the activity and stability of the product, and the pre-freezing temperature and holding time are very critical; in the primary drying (sublimation drying) stage, due to the extremely high selectivity of landiolol hydrochloride for β1 receptors, the temperature, time and vacuum degree need to be precisely controlled during the freeze-drying process to ensure the retention of drug activity; in the secondary drying (analysis drying) stage, it is necessary to focus on regulating the temperature and vacuum degree to further remove the remaining water, while avoiding the destruction of the drug structure, and ensuring the stability and resolubility of the drug. Only by simultaneously controlling multiple parameters in the freeze-drying process within a specific range can landiolol hydrochloride for injection with good stability and fast resolubility be obtained.
[0143] The embodiments of the present application are described above, but the present application is not limited to the above-mentioned specific implementation modes. The above-mentioned specific implementation modes are merely illustrative and not restrictive. Under the guidance of the present application, ordinary technicians in this field can also make many forms without departing from the purpose of the present application and the scope of protection of the claims, all of which are within the protection of the present application.
Claims
1. A method for preparing a beta-blocker for injection, characterized in that: The steps include: 1) preparing a liquid: mixing a prescribed amount of landiolol hydrochloride, a prescribed amount of a lyophilization protective agent and a portion of a solvent, stirring and dissolving, adjusting the pH value of the liquid with a sodium hydroxide solution, and diluting the volume to a predetermined volume with the solvent to obtain a landiolol hydrochloride liquid; 2) Filtration: filtering the landiolol hydrochloride solution obtained in step 1) using a filter membrane; 3) Filling: filling the landiolol hydrochloride solution filtered in step 2) into an injection bottle to obtain a landiolol hydrochloride product 1; 4) semi-plugging: performing semi-plugging treatment on the landiolol hydrochloride product 1 to obtain the landiolol hydrochloride product 2; 5) freeze drying: freeze drying the landiolol hydrochloride product 2 through pre-freezing, primary drying and secondary analytical drying steps to obtain the landiolol hydrochloride product 3; 6) nitrogen filling, plugging, and unpacking: nitrogen filling the landiolol hydrochloride product 3 under vacuum, and then plugging in a freeze dryer before unpacking; 7) Capping: The product obtained in step 6) is capped to obtain the final landiolol hydrochloride product 4.
2. The method for preparing a beta-blocker for injection according to claim 1, characterized in that: The pre-freezing process in step 5) is: placing the landiolol hydrochloride product 2 into a freeze-drying chamber, setting the temperature of the heat transfer fluid to -30°C, so as to reduce the temperature of the landiolol hydrochloride product 2 to -30°C ± 5°C within 60 minutes, and then maintaining it within this temperature range for 60 to 120 minutes.
3. The method for preparing a beta-blocker for injection according to claim 2, characterized in that: The primary drying process in step 5) is as follows: after the pre-freezing process is completed, when the vacuum degree in the freeze drying chamber reaches 0.15 mbar, the temperature is increased to slowly increase the temperature of the heat transfer liquid to 10-15°C, and the heating time is controlled within 60 minutes, followed by keeping the temperature at this temperature for 180-720 minutes.
4. The method for preparing a beta-blocker for injection according to claim 3, characterized in that: The two analytical drying processes in step 5) are as follows: first analytical drying: after the first drying process is completed, the heat transfer system is started to raise the temperature of the thermal fluid to 30-40°C, the heating time is controlled within 60 minutes, and then the temperature is kept at this temperature for 60-120 minutes, and at the same time, the vacuum degree in the freeze drying chamber is maintained at 0.1 mbar; second analytical drying: after the first analytical drying is completed, the vacuum degree in the freeze drying chamber is gradually adjusted to 0 mbar, and while adjusting the vacuum degree, the temperature of the thermal fluid is maintained at 30-40°C for 60-120 minutes.
5. The method for preparing a beta-blocker for injection according to claim 4, characterized in that: The temperature of the heat transfer fluid in the first desorption drying is the same as the temperature of the heat transfer fluid in the second desorption drying.
6. The method for preparing a beta-blocker for injection according to claim 5, characterized in that: The pH value of the landiolol hydrochloride solution is 5.5-6.
5.
7. The method for preparing a beta-blocker for injection according to any one of claims 1 to 6, characterized in that: The composition of the beta-blocker for injection comprises: 50-55 parts of landiolol hydrochloride, 50-55 parts of lyophilization protective agent, appropriate amount of sodium hydroxide and appropriate amount of solvent.
8. The method for preparing a beta-blocker for injection according to claim 7, characterized in that: The lyophilization protective agent is D-mannitol.
9. The method for preparing a beta-blocker for injection according to claim 8, characterized in that: The solvent is used to adjust the volume of the mixture of landiolol hydrochloride and the lyoprotectant to a predetermined volume of each preparation.
10. The beta-blocker for injection prepared by the method according to any one of claims 1 to 9, wherein the beta-blocker for injection is preferably landiolol hydrochloride for injection, and the dosage form is sterile powder for injection.
Citation Information
Patent Citations
Landiolol hydrochloride active ingredient-containing medicinal composition for injection and preparation method thereof
CN101732319A
Landiolol hydrochloride pharmaceutical compositions and preparation methods thereof
CN102232930A
Landiolol hydrochloride medicine composition for injection and preparation method thereof
CN102475706A
Hydrochloric acid landiolol freeze-dried powder injection and preparation process thereof
CN106265539A
Preparation method of azithromycin freeze-dried powder injection
CN112618496A
